Lorcaserin
- Generic Name
- Lorcaserin
- Drug Type
- Small Molecule
- Chemical Formula
- C11H14ClN
- CAS Number
- 616202-92-7
- Unique Ingredient Identifier
- 637E494O0Z
- Background
Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.
In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug. This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer.
- Indication
For the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.
- Associated Conditions
- Obesity
Predictors of Lorcaserin-Induced Weight Loss
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 32
- Registration Number
- NCT03353220
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT03338296
- Locations
- 🇺🇸
Phoenix Clinical LLC, Phoenix, Arizona, United States
🇺🇸Oviedo Medical Research, LLC, Oviedo, Florida, United States
🇺🇸Long Beach Clinical Trial Services, Inc, Long Beach, California, United States
Rebalancing the Serotonergic System in Cocaine Dependence
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03266939
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 15
- Registration Number
- NCT03253926
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Treatment With Lorcaserin for Cocaine Use: The TLC Study
- Conditions
- Cocaine Use Disorder
- Interventions
- Drug: Placebo Oral TabletBehavioral: Substance use counselingBehavioral: ACASIDiagnostic Test: Cocaine metabolitesBehavioral: Ecological Momentary Assessment (EMA)Behavioral: Balloon Analogue Risk Task (BART)Behavioral: Qualitative Exit Interview
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Glenn-Milo Santos
- Target Recruit Count
- 22
- Registration Number
- NCT03192995
- Locations
- 🇺🇸
San Francisco Department of Public Health, San Francisco, California, United States
Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03169816
- Locations
- 🇺🇸
Substance Treatment and Research Service (STARS), Columbia University, New York, New York, United States
Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
- Conditions
- Opioid AbuseOpioid DependenceOpioid-Related DisordersOpioid Use
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 32
- Registration Number
- NCT03143855
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Gene-by-Stress Interactions in Intervention Studies Significance
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 7
- Registration Number
- NCT03011645
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Lorcaserin in the Treatment of Cocaine Use Disorder
- Conditions
- Cocaine-Related Disorders
- Interventions
- Drug: Placebo Oral Capsule
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 272
- Registration Number
- NCT03007394
- Locations
- 🇺🇸
Pacific Treatment and Research Center, La Jolla, California, United States
🇺🇸Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸George Washington University, Washington, District of Columbia, United States
Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 17
- Registration Number
- NCT02932215
- Locations
- 🇺🇸
Columbia Substance Treatment and Research Service, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.